{"id":726,"date":"2026-04-16T02:05:09","date_gmt":"2026-04-16T02:05:09","guid":{"rendered":"https:\/\/nueva.genolifeadn.com\/?page_id=726"},"modified":"2026-05-14T17:15:18","modified_gmt":"2026-05-14T17:15:18","slug":"trombopanel-genetico","status":"publish","type":"page","link":"https:\/\/nueva.genolifeadn.com\/en\/trombopanel-genetico\/","title":{"rendered":"Genetic Thrombosis Panel"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\tGenetic Thrombosis Panel\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Trombopanel Genetic is especially beneficial for individuals with a family history of thrombophilia, where the risk of developing thrombosis can be as high as 50%.<\/p>

One of the main factors that cause or increase the risk of miscarriage is blood clotting.
According to official WHO data, 20% of pregnancies worldwide end in miscarriage.<\/p>

In Latin America, it is estimated that one third of all women have a miscarriage at some time in their reproductive years.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\tAvoid complications and chart a healthy trajectory to avoid risk events\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Fortalece tus conocimientos sobre ti para mejorar tu salud.<\/strong><\/p>

It is important to mention that not all individuals with these mutations will develop health problems; however, in the presence of other risk factors, such as family history or unhealthy lifestyles, the risk may be increased. Therefore, the detection of these mutations can be useful to establish preventive strategies, such as folate supplementation, to reduce homocysteine levels and the associated risk, as well as personalized preventive and therapeutic measures to reduce the risk of thrombosis and stroke in these patients.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u00bfEn qu\u00e9 se basa el estudio?<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t

This analysis detects mutations in specific genes such as AGT, F2, F5, F7, FGB, MTR, MTRR, MTHFR, and SERPINE1<\/strong>. For example, mutations in the F2 and F5 genes can significantly increase the risk of thrombotic events.<\/p>

Adem\u00e1s, se buscan variantes gen\u00e9ticas C677T y A1298C en el gen MTHFR asociadas con alteraciones en el metabolismo del folato y pueden llevar a niveles elevados de homociste\u00edna en la sangre, conocida como hiperhomocisteinemia. La hiperhomocisteinemia es un factor de riesgo para enfermedades tromboemb\u00f3licas y cardiovasculares. La mutaci\u00f3n C677T, en particular, resulta en una variante termol\u00e1bil de la enzima MTHFR con capacidad reducida para metabolizar la homociste\u00edna, lo que puede aumentar el riesgo de trombosis venosa profunda y otras complicaciones cardiovasculares.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n
\n\t\t\t\t\t
<\/path><\/svg><\/span><\/path><\/svg><\/span>SNPs<\/span><\/path><\/svg><\/div>